v3.24.1.u1
SUPPLEMENTAL INFORMATION
 3 Months Ended
Mar. 31, 2024
Geographic Areas, Long-Lived Assets [Abstract]  
Supplemental information SUPPLEMENTAL INFORMATION
The Company operates in a single reportable segment.
The following table presents long-lived assets by location:
March 31,
2024		December 31,
2023
 UnauditedAudited
United States$45,358 $41,634 
Israel8,290 8,317 
Switzerland10,940 7,733 
Others6,240 5,179 
Total long lived assets$70,828 $62,863 

Restructuring
In November 2023, the Company announced a series of actions to strengthen and optimize its business operations to support near-term growth drivers and long-term value creation. The plan included a reduction in headcount of approximately 200 employees or 13% of the Company's then current workforce. The Company incurred restructuring costs (including severance pay, garden leave payments, etc.) in the amount of $2,031 and $6,231 for the three months ended March 31, 2024 and the year ended December 31, 2023, respectively, as follows:
Three months ended March 31,Year ended December 31,
2023
2024
UnauditedAudited
Cost of revenues$52 $262 
Research, development and clinical studies275 2,070 
Sales and marketing1,539 2,404 
General and administrative164 1,495 
Total restructuring cost
$2,031 $6,231 
Restructuring costs paid during the period
$5,128 $2,753 

These restructuring costs were offset by accrual reversals for the three months ended March 31, 2024 and the year ended December 31, 2023 in the amount of $369 and $3,041, respectively, which relate to the terminated employees' exits from the Company’s cash incentive plans. These restructuring costs were further offset by forfeited equity-based compensation expense reversals for the three months ended March 31, 2024 and the year ended December 31, 2023 in the amount of $1,661 and $9,313, respectively, which relate to the terminated employees' exits from the Company’s equity incentive plan.